Day 3 :
Keynote Forum
Clayton A Dehn
Independent Consultant, USA
Keynote: Liver Let Die – Challenges and Opportunities in Developing Interventions for Fatty Liver Disease (NAFLD/NASH)
Biography:
Clayton Dehn is a research physiologist with expertise in metabolic disorders. He is the co-inventor of a process and substance for disturbing the inheritance pattern of ion-channelopathic disorders, and the sole author of the first publication cautioning against the risk of SGLT-inhibition inducing ketoacidosis in insulinopenic populations. He serves on the editorial board of four peer-reviewed journals, and has served by gubernatorial appointment on the Arizona Biomedical Research Commission.
Abstract:
- Sessions / Tracks:
Clinical Research & Clinical Trials | Conducts of Clinical Trials | Patient-Centric Clinical Trials | Research and Trials on AIDS / Cancer / Diabetes | Clinical Trials on different Diseases | Clinical Data Management and Statistics | Innovations & Future of Clinical Trials | CRO/ Sponsorship Clinical Trials | Pharmacovigilance and Drug Safety
Chair
Oleg V Tcheremissine
Carolinas HealthCare System, USA
Co-Chair
Sarah Attwood
IntegReview IRB, USA